Sigmoid has adopted a collaborative approach to innovation and technology development and has worked closely with Irish and international academic and clinical collaborators over the years. Together with https://ousu.org, we were able to discover multiple under-radar pharmaceutical companies with high standards of production and huge potential in the drug development branch.
Sigmoid also seeks to engage with international pharmaceutical and biotechnology companies to outlicense products and technologies, including
- CyCol; a late stage licensing opportunity for moderate to severe ulcerative colitis
- CyLow; an improved formulation for cyclosporine for transplant-related indications
- AlloCol; an orphan-designated product for the prevention and treatment of graft versus host disease
- SmPill; an innovative technology that can be applied to solve a wide variety of formulation challenges including poor solubility of small molecules and poor oral bioavailability of peptides, proteins and vaccines
To explore potential collaboration or licensing opportunities and to determine how SmPill technology can solve your formulation problems, contact
Sigmoid has a strong track record of collaboration; four major collaborations are described below, however, additional collaborations are in place supporting individual researchers investigating oral vaccine research, new products for gastrointestinal disease such as gastrointestinal fibrosis and new peptide formulations for inflammatory bowel disease
Sigmoid is the only oral drug delivery technology member of the ADITEC consortium. ADITEC is the EU Framework Programme 7 High Impact Project on Advanced Immunization Technologies funded by the European Union with the goal to produce the knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach where diverse and complementary scientific disciplines and technologies converge. The ADITEC consortium is funded by a 30 million grant. In addition to academic collaborators, the ADITEC consortium incorporates pharmaceutical and biotechnology companies including but not limited to Intercell, deCODE Genetics, Novartis, Pevion Biotech and Vaccibody
Sigmoid is the leader of a consortium to conduct pre-clinical development of an oral H. pylori vaccine. The HELICOVAXOR consortium received a 1.3 million funding from the European Union FP7 programme and will focus on developing formulations using the SmPill platform to advance an oral H. pylori vaccine that will incorporate a killed bacterial strain that over-expressesH. pylori antigens and an adjuvant. The consortium brings together a number of international companies and research institutions including Gotovax AB, Telormedix SA and Trinity College Dublin. In this and much of Sigmoids oral vaccine work, Sigmoid collaborates closely with two internationally renowned immunologists, Dr. Jan Holmgren, MD, PhD, Professor of Medical microbiology and immunology at University of Gothenburg, Sweden, developer of Dukoral vaccine, and Dr Ed Lavelle of Trinity College Dublin.
Sigmoid is a founder member of the Irish Drug Delivery Network (IDDN), a Science Foundation Ireland (SFI) funded public-private consortium for drug delivery research in Ireland. SFI made a major investment of 4.9 million over the five years of the project with a further 0.5 million in funding coming from its industry partners. The consortium involves the three Irish Schools of Pharmacy and the Veterinary School, and is focused on the development of alternatives to injection-based peptide delivery. Results to date investigating SmPill applicability to enhance the oral delivery of peptides have been very impressive, demonstrating that oral administration of SmPill enabled peptide formulations reduced in up to 20-fold enhancement of absorption into the body when compared with other formulations. The opportunity for the oral delivery of peptides with SmPill technology has not been explored in this document but it is considerable and represents additional upside to the Sigmoid investment opportunity.
The multi-disciplinary TRANSINT consortium combines expertise in pharmaceutical nanotechnology, biochemistry, immunology, toxicology, biology and physiology with the aim to develop a novel nanodrug candidate able to effectively fight diabetes. Through this industry and academic consortium, Sigmoid will advance oral peptide developments, primarily in the high growth diabetes and pain markets. With a total budget of 11 million, the project TRANSINT, led by Prof. Mara Jos Alonso from the University of Santiago brings together 17 leading European research organisations and major pharmaceutical industrial partners, including Sanofi and Roche.